Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia.

about

Nanomedicine strategies for hematological malignancies: what is next?Clinical potential of elacytarabine in patients with acute myeloid leukemia.F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.

P2860

Q38270098-BF7146E0-E442-435F-A74A-48EEB9A737E4 Q38282095-779A57FC-709A-4285-9CFC-92BC78749460 Q54264719-225FC6B7-5850-4297-AC0D-14630B388D98

P2860

Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia.

Item

http://www.wikidata.org/entity/Q38078423

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia.

@en

type

Item

label

Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia.

@en

prefLabel

Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia.

@en

P1476

Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia.

@en

P2093

Ciara Freeman

http://www.w3.org/2001/XMLSchema#string

Francis J Giles

http://www.w3.org/2001/XMLSchema#string

Niamh Keane

http://www.w3.org/2001/XMLSchema#string

Ronan Swords

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

Long term cultured HL-60 cells are intrinsically resistant to Ara-C through high CDA activity.

Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia

Potential mechanisms of resistance to cytarabine in AML patients.

Nucleoside analogues: mechanisms of drug resistance and reversal strategies.

Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia

Cytarabine dose for acute myeloid leukemia.

P304

9-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/EHM.12.68

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23373775

http://www.w3.org/2001/XMLSchema#string

Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia.

about

P2860

P2860

Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698